Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 29,101 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 1 Clear all

Conditions: AML, Acute Myeloid Leukemia, Myelodysplastic Disorders
Interventions: Idarubicin, Sorafenib, Ara-C; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 60 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cleft Palate
Interventions: Oral acetaminophen, Ofirmev®, Opioid only; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 5 Months to 5 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
Interventions: GTB-5550; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alzheimer Disease
Interventions: BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Myeloproliferative Neoplasms (MPNs)
Interventions: DMR-001, Ruxolitinib; Drug
Lead sponsor: Damora Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 25
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 20 more

Conditions: Breast Cancer
Interventions: Herceptin, Taxol, Fluorouracil, Cytoxan, Epirubicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: L-778,123, paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: [14C]-brensocatib; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: AFX3772, Prevnar 13, Prevnar 20; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more

Conditions: Gram-Positive Infections
Interventions: IV Tedizolid Phosphate, Oral Suspension Tedizolid Phosphate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Day to 24 Months
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 4 more

Conditions: Multiple Myeloma
Interventions: Subcutaneous bortezomib; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: West Hollywood, California

Conditions: Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
Interventions: WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim), Montanide adjuvant; Biological · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions: VERVE-102, Placebo; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DeSoto, Texas

Conditions: Smoking Cessation
Interventions: Ganaxolone, Nicotine Patch; Drug
Lead sponsor: Jed E. Rose; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more

Conditions: Primary Immune Thrombocytopenia
Interventions: PF-06835375; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Healthy Volunteers
Interventions: Cendakimab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Verruca Vulgaris, Molluscum Contagiosum
Interventions: Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP); Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 4 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Lymphoma, Follicular
Interventions: Atezolizumab (MPDL3280A) [TECENTRIQ], Lenalidomide, Obinutuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Birmingham, Alabama • Miami, Florida • Louisville, Kentucky + 2 more

Conditions: Hypertension
Interventions: olmesartan medoxomil, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more

Conditions: Lymphoma
Interventions: filgrastim, recombinant human stem cell factor, cyclophosphamide, cytarabine, etoposide, melphalan, mitoxantrone hydrochloride, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
Interventions: Bevacizumab, Pemetrexed, Vitamin B12, Folate, Dexamethasone; Drug
Lead sponsor: Heather Wakelee; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 4
States / cities: Stanford, California • Lebanon, New Hampshire • Voorhees Township, New Jersey + 1 more

Conditions: Fungal Infection
Interventions: Placebo, Rezafungin; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma
Interventions: Casdatifan, Zimberelimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Pregnancy Related, Narcolepsy
Interventions: Pitolisant, Comparator Products; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: Female only
Enrollment: 1,329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Morrisville, North Carolina

Search by objective public record fields.

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

GTB-5550 in Advanced Solid Tumors

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

Cold Atmospheric Plasma Device Extension Study

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

Safety and Pharmacokinetics of Rezafungin

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

WAKIX® (Pitolisant) Pregnancy Registry